Michael Cotten, MD; Kathy J
Michael Cotten, MD; Kathy J. after the primary series, and had extra serum available. Subjects were also eligible if they completed a 2-dose primary series (at 2 and 4 months) of FMK PRP-OMP vaccine at one center (Rochester) able to draw blood samples 4C6 weeks thereafter. The primary outcome was geometric mean anti-PRP titer (GMT) […]